Skip to main content Skip to search Skip to search

Medical Psychopharmacology

Clinical Handbook of Psychotropic Drugs For Children and Adolescents

by (author) Dean Elbe, Tyler R. Black & Ian R. McGrane

edited by Ric M. Procyshyn

Publisher
Hogrefe Publishing
Initial publish date
Jun 2018
Category
Psychopharmacology, Psychiatric, Child & Adolescent
  • Spiral bound

    ISBN
    9780889375505
    Publish Date
    Jun 2018
    List Price
    $138.95
  • Spiral bound

    ISBN
    9780889376250
    Publish Date
    Mar 2023
    List Price
    $145.95

Add it to your shelf

Where to buy it

Description

Quick and comprehensive information on psychotropic drugs for children and adolescents.

  • Accurate and up-to-date
  • Specific to children and adolescents
  • Charts and tables help decision-making
  • Icons and full color

The Clinical Handbook of Psychotropic Drugs for Children and Adolescents has become a standard reference and working tool for psychiatrists, pediatricians, psychologists, physicians, pharmacists, nurses, and other mental health professionals.

  • Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions...) for a quick overview of treatment options
  • Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, nursing implications, and much more—all you need to know for each class of drug
  • Potential interactions and side effects summarized in comparison charts
  • With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek
  • Clearly written patient and caregiver information sheets for download as printable PDF files

This book is a must for all mental health professionals working with children and adolescents who need an up-to-date, easy-to use, comprehensive summary of all the most relevant information about psychotropic drugs.

  • Drugs for ADHD thoroughly revised and updated
  • Antipsychotics with many changes and additions, including fully revised lab tests/monitoring
  • Antidepressants fully revised, including new sections on irreversible MAO-B inhibitor and serotonin modulator and stimulator (SMS), revised frequency of adverse effects table and switching strategies recommendations
  • Hypnotics completely revised
  • Mood stabilizers fully revised and a new toxicity comparison table added
  • Drugs of abuse and treatment of substance use disorder comprehensively revised
  • New unapproved treatments with significant updates, including: anti-inflammatories and NMDA agents in anxiety/OCD, cannabis use, and irritability of autism
  • New agents include: TGAs N-arylpiperazine (brexpiprazole) and phenylpiperazine (cariprazine), hypnotics orexin receptor antagonist (hypnotic suvorexant) and selective melatonin agonist (tasimelteon), antidepressant bisarylsulfanyl amine (vortioxetine)
  • New formulations and trade names include: Adasuve, Alprazolam Intensol, Aptensio XR, Aristada, Belbuca, Belsomra, Brintellix, Bunavail, Cotempla XR-ODT, Dyanavel XR,Eldepryl, EMSAM, Evekeo, Hemangeol, Hetlioz, Innopran XL, Invega Trinza, Khedezla, Metadol-D, Mydayis, NyQuil, Quillichew ER, Quillivant XR, Rexulti, Som-Pam, Tegretol (liquid), Trintellix, Versacolz, Vraylar, Vyvanse, Zelapar, Zenzedi

About the authors

Other titles by

Other titles by